Literature DB >> 19034303

Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease.

Heather N Reich1, Gavin Y Oudit, Josef M Penninger, James W Scholey, Andrew M Herzenberg.   

Abstract

Angiotensin converting enzyme (ACE) generates angiotensin II from angiotensin I, which plays a critical role in the pathophysiology of diabetic nephropathy. However, ACE2 generates angiotensin 1-7, which may protect the kidney by attenuating the effects of angiotensin II, since deletion of the Ace2 gene leads to glomerulosclerosis in mice, and pharmacologic inhibition of ACE2 exacerbates experimental diabetic nephropathy. We measured ACE2 and ACE expression in renal biopsies of patients with kidney disease due to type 2 diabetes to determine if the expression pattern is specific to diabetic nephropathy. ACE2 and ACE mRNA levels were measured by real-time PCR in laser microdissected renal biopsies from 13 diabetic and 8 control patients. ACE2 mRNA was significantly reduced by more than half in both the glomeruli and proximal tubules of the diabetic patients compared to controls, but ACE mRNA was increased in both compartments. There was a significant parallel decrease in ACE2 protein expression, determined by immunohistochemistry, in proximal tubules, a pattern not found in 12 patients with focal glomerulosclerosis or 10 patients with chronic allograft nephropathy. Our results suggest that the kidney disease of patients with type 2 diabetes is associated with a reduction in ACE2 gene and protein expression and this may contribute to the progression of renal injury.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19034303     DOI: 10.1038/ki.2008.497

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  96 in total

1.  Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Janae Joyner; Jasmina Varagic
Journal:  Adv Pharmacol       Date:  2010

Review 2.  ACE and ACE2 in kidney disease.

Authors:  Sonoo Mizuiri; Yasushi Ohashi
Journal:  World J Nephrol       Date:  2015-02-06

Review 3.  The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.

Authors:  Xiao C Li; Jianfeng Zhang; Jia L Zhuo
Journal:  Pharmacol Res       Date:  2017-06-12       Impact factor: 7.658

Review 4.  ACE2: more of Ang-(1-7) or less Ang II?

Authors:  Carlos M Ferrario
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-01       Impact factor: 2.894

5.  Spironolactone rescues renal dysfunction in obstructive jaundice rats by upregulating ACE2 expression.

Authors:  Er-Liang Kong; Jin-Min Zhang; Ni An; Yong Tao; Wei-Feng Yu; Fei-Xiang Wu
Journal:  J Cell Commun Signal       Date:  2018-06-07       Impact factor: 5.782

6.  Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice.

Authors:  Esam S B Salem; Nadja Grobe; Khalid M Elased
Journal:  Am J Physiol Renal Physiol       Date:  2014-01-22

Review 7.  New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism.

Authors:  Carlos M Ferrario
Journal:  Hypertension       Date:  2009-12-21       Impact factor: 10.190

8.  [Angiotensin-(1-7) protects cardiac myocytes against high glucose-induced injury by inhibiting ClC-3 chloride channels].

Authors:  Shao-Ai Ccai; Jing-Fu Chen; Mei-Ji Chen; Jian-Cong Lin; Jian-Qiang Feng; Kai Lin; Xi-Mei Zhi; Wei-Jie Zhang; Wen Wu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-07-20

9.  Daily exercise training protects against albuminuria and angiotensin converting enzyme 2 shedding in db/db diabetic mice.

Authors:  Hari K Somineni; Gregory P Boivin; Khalid M Elased
Journal:  J Endocrinol       Date:  2014-04-22       Impact factor: 4.286

10.  Does ACE2 contribute to the development of hypertension?

Authors:  Mark C Chappell
Journal:  Hypertens Res       Date:  2009-12-18       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.